Advantage of guided de-escalation of dual antiplatelet therapy seen in younger patients
A pre-specified analysis of the TROPICAl-ACS study indicates that de-escalating dual antiplatelet therapy (DAPT), as guided by platelet function testing, after percutaneous coronary intervention...
First patient enrolled in phase II of REFLECT study of TriGuard 3
Keystone Heart announced the launch of phase II of the REFLECT trial, which is evaluating the next-generation TriGuard 3 cerebral protection device. According to a...
US FDA approve EchoMD AutoEF software for calculating left ventricular ejection fraction
Bay Labs has received US FDA 510(k) clearance for its its EchoMD AutoEF software product for the fully automated clip selection and calculation of...
Caladrius receives FDA regenerative medicine advanced therapy designation for its CD34+ Cell therapy for...
Caladrius has revealed that the US FDA has granted regenerative medicine advanced therapy (RMAT) designation to its late-stage CD34+ cell therapy programme for the...
(Visited 9,819 times, 1 visits today)
